Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-168192a0c6d5270d5bcdb3cfa6cdd926"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-168192a0c6d5270d5bcdb3cfa6cdd926"/>
<resource>
<Composition>
<id value="composition-en-168192a0c6d5270d5bcdb3cfa6cdd926"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-168192a0c6d5270d5bcdb3cfa6cdd926"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-168192a0c6d5270d5bcdb3cfa6cdd926</b></p><a name="composition-en-168192a0c6d5270d5bcdb3cfa6cdd926"> </a><a name="hccomposition-en-168192a0c6d5270d5bcdb3cfa6cdd926"> </a><a name="composition-en-168192a0c6d5270d5bcdb3cfa6cdd926-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/04/292/001 – 30 mg carton with 14 tablets</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - mimpara</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/04/292/001 – 30 mg carton with 14 tablets"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp168192a0c6d5270d5bcdb3cfa6cdd926"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - mimpara"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Mimpara is and what it is used for</li><li>What you need to know before you take Mimpara</li><li>How to take Mimpara</li><li>Possible side effects</li><li>How to store Mimpara</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What mimpara is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What mimpara is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Mimpara works by controlling the levels of parathyroid hormone (PTH), calcium and phosphorous in your body. It is used to treat problems with organs called parathyroid glands. The parathyroids are four small glands in the neck, near the thyroid gland, that produce parathyroid hormone (PTH).</p><p>Mimpara is used in adults:</p><ul><li>to treat secondary hyperparathyroidism in adults with serious kidney disease who need dialysis to clear their blood of waste products.</li><li>to reduce high levels of calcium in the blood (hypercalcaemia) in adult patients with parathyroid cancer.</li><li>to reduce high levels of calcium in the blood (hypercalcaemia) in adult patients with primary hyperparathyroidism when removal of the gland is not possible.</li></ul><p>Mimpara is used in children aged 3 years to less than 18 years of age:</p><ul><li>to treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products, whose condition is not controlled with other treatments.</li></ul><p>In primary and secondary hyperparathyroidism too much PTH is produced by the parathyroid glands. Primary means that the hyperparathyroidism is not caused by any other condition and secondary<br/>means that the hyperparathyroidism is caused by another condition, e.g. kidney disease. Both primary and secondary hyperparathyroidism can cause the loss of calcium in the bones, which can lead to bone pain and fractures, problems with blood and heart vessels, kidney stones, mental illness and coma.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take mimpara"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take mimpara"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Mimpara if you are allergic to cinacalcet or any of the other ingredients of this medicine (listed in section 6).</p><p>Do not take Mimpara if you have low levels of calcium in your blood. Your doctor will monitor your blood calcium levels.</p><p>Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Mimpara.</p><p>Before you start taking Mimpara, tell your doctor if you have or have ever had:</p><ul><li>seizures (fits or convulsions). The risk of having seizures is higher if you have had them before;</li><li>liver problems;</li><li>heart failure.</li></ul><p>Mimpara reduces calcium levels. Life threatening events and fatal outcomes associated with low calcium levels (hypocalcaemia) have been reported in adults and children treated with Mimpara.</p><p>Please tell your doctor if you experience any of the following which may be signs of low calcium levels: spasms, twitches, or cramps in your muscles, or numbness or tingling in your fingers, toes or around your mouth or seizures, confusion or loss of consciousness while being treated with Mimpara.</p><p>Low calcium levels can have an effect on your heart rhythm. Tell your doctor if you experience an unusually fast or pounding heartbeat, if you have heart rhythm problems, or if you take medicines known to cause heart rhythm problems, while taking Mimpara.</p><p>For additional information see section 4. During treatment with Mimpara, tell your doctor:</p><ul><li>if you start or stop smoking, as this may affect the way Mimpara works.</li></ul><p>Children and adolescents Children under the age of 18 with parathyroid cancer or primary hyperparathyroidism must not take Mimpara.</p><p>If you are being treated for secondary hyperparathyroidism, your doctor should monitor your calcium levels before starting treatment with Mimpara and during treatment with Mimpara. You should inform your doctor if you experience any of the signs of low calcium levels as described above.</p><p>It is important that you take your dose of Mimpara as advised by your doctor.</p><p>Other medicines and Mimpara Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines particularly etelcalcetide or any other medicines that lower the level of calcium in your blood.</p><p>You should not receive Mimpara together with etelcalcetide.</p><p>Tell your doctor if you are taking the following medicines</p><p>Medicines such as these can affect how Mimpara works:</p><ul><li>medicines used to treat skin and fungal infections (ketoconazole, itraconazole and voriconazole);</li><li>medicines used to treat bacterial infections (telithromycin, rifampicin and ciprofloxacin);</li><li>a medicine used to treat HIV infection and AIDS (ritonavir);</li><li>a medicine used to treat depression (fluvoxamine).</li></ul><p>Mimpara may affect how medicines such as the following work:</p><ul><li>medicines used to treat depression (amitriptyline, desipramine, nortriptyline and clomipramine);</li><li>a medicine used to relieve cough (dextromethorphan);</li><li>medicines used to treat changes in heart rate (flecainide and propafenone);</li><li>a medicine used to treat high blood pressure (metoprolol).</li></ul><p>Mimpara with food and drink Mimpara should be taken with or shortly after food.</p><p>Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Mimpara has not been tested in pregnant women. In case of pregnancy, your doctor may decide to modify your treatment, as Mimpara might harm the unborn baby.</p><p>It is not known whether Mimpara is excreted in human milk. Your doctor will discuss with you if you should discontinue either breast-feeding or treatment with Mimpara.</p><p>Driving and using machines Dizziness and seizures have been reported by patients taking Mimpara. If you experience these side effects, do not drive or operate machines.</p><p>Mimpara contains lactose If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p></div>
</text>
</section>
<section>
<title value="3. How to take mimpara"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take mimpara"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are unsure. Your doctor will tell you how much Mimpara you must take.</p><p>Mimpara must be taken orally, with or shortly after food. The tablets must be taken whole and are not to be chewed, crushed or divided.</p><p>Mimpara is also available as granules in capsules for opening. Children who require doses lower than 30 mg, or who are unable to swallow tablets should receive Mimpara granules.</p><p>Your doctor will take regular blood samples during treatment to monitor your progress and will adjust your dose if necessary.</p><p>If you are being treated for secondary hyperparathyroidism The usual starting dose for Mimpara in adults is 30 mg (one tablet) once per day.</p><p>The usual starting dose of Mimpara for children aged 3 years to less than 18 years of age is no more than 0.20 mg/kg of body weight daily.</p><p>If you are being treated for parathyroid cancer or primary hyperparathyroidism The usual starting dose for Mimpara in adults is 30 mg (one tablet) twice per day.</p><p>If you take more Mimpara than you should If you take more Mimpara than you should you must contact your doctor immediately. Possible signs of overdose include numbness or tingling around the mouth, muscle aches or cramps and seizures.</p><p>If you forget to take Mimpara Do not take a double dose to make up for a forgotten dose.</p><p>If you have forgotten a dose of Mimpara, you should take your next dose as normal.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Please tell your doctor immediately:</p><ul><li>If you start to get numbness or tingling around the mouth, muscle aches or cramps and seizures. These may be signs that your calcium levels are too low (hypocalcaemia).</li><li>If you experience swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing (angioedema).</li></ul><p>Very common: may affect more than 1 in 10 people</p><ul><li>nausea and vomiting, these side effects are normally quite mild and do not last for long.</li></ul><p>Common: may affect up to 1 in 10 people</p><ul><li>dizziness</li><li>numbness or tingling sensation (paraesthesia)</li><li>loss (anorexia) or decrease of appetite</li><li>muscle pain (myalgia)</li><li>weakness (asthenia)</li><li>rash</li><li>reduced testosterone levels</li><li>high potassium levels in the blood (hyperkalaemia)</li><li>allergic reactions (hypersensitivity)</li><li>headache</li><li>seizures (convulsions or fits)</li><li>low blood pressure (hypotension)</li><li>upper respiratory infection</li><li>breathing difficulties (dyspnoea)</li><li>cough</li><li>indigestion (dyspepsia)</li><li>diarrhoea</li><li>abdominal pain, abdominal pain upper</li><li>constipation</li><li>muscle spasms</li><li>back pain</li><li>low calcium levels in the blood (hypocalcaemia).</li></ul><p>Not known: frequency cannot be estimated from available data</p><ul><li>Hives (urticaria)</li><li>Swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing (angioedema)</li><li>Unusually fast or pounding heart beat which may be associated with low levels of calcium in your blood (QT prolongation and ventricular arrhythmia secondary to hypocalcaemia).</li></ul><p>After taking Mimpara a very small number of patients with heart failure had worsening of their condition and/or low blood pressure (hypotension).</p><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store mimpara"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store mimpara"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month. Do not use this medicine after the expiry date which is stated on the carton and bottle. The expiry date refers to the last day of that month.</p><p>This medicinal product does not require any special storage conditions. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Mimpara contains</p><ul><li>The active substance is cinacalcet. Each film-coated tablet contains 30 mg, 60 mg or 90 mg of cinacalcet (as hydrochloride).</li><li>The other ingredients are:</li></ul><ul><li>Pre-gelatinised maize starch</li><li>Microcrystalline cellulose</li><li>Povidone</li><li>Crospovidone</li><li>Magnesium stearate</li><li>Colloidal anhydrous silica</li></ul><ul><li>The tablets are coated with:</li></ul><ul><li>Carnauba wax</li><li>Opadry green (containing lactose monohydrate, hypromellose, titanium dioxide (E171), glycerol triacetate, FD&C Blue (E132), iron oxide yellow (E172))</li><li>Opadry clear (containing hypromellose, macrogol)</li></ul><p>What Mimpara looks like and contents of the pack Mimpara is a light green film-coated tablet. They are oval-shaped and have 30 , 60 or 90 marked on one side and AMG on the other side.</p><p>30 mg tablets are approximately 9.7 mm long and 6.0 mm wide. 60 mg tablets are approximately 12.2 mm long and 7.6 mm wide. 90 mg tablets are approximately 13.9 mm long and 8.7 mm wide.</p><p>Mimpara is available in blisters of 30 mg, 60 mg or 90 mg film-coated tablets. Each blister pack contains either 14, 28 or 84 tablets in a carton. Mimpara is available in bottles of 30 mg, 60 mg or 90 mg film-coated tablets, inside a carton. Each bottle holds 30 tablets.</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder and Manufacturer Amgen Europe B.V. Minervum 74817 ZK Breda The Netherlands</p><p>Marketing Authorisation Holder Amgen Europe B.V. Minervum 74817 ZK Breda The Netherlands</p><p>Manufacturer Amgen NV Telecomlaan 5-7 1831 Diegem Belgium</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.</p><p>Belgi /Belgique/Belgien s.a. Amgen n.v. Tel/T l: +32 (0)2 7752Lietuva Amgen Switzerland AG Vilniaus filialas Tel: +370 5 219 7</p><p>.: +359 (0)2 424 7Luxembourg/Luxemburg s.a. Amgen<br/>Belgique/Belgien Tel/T l: +32 (0)2 7752 esk republika Amgen s.r.o. Tel: +420 221 773 Magyarorsz g Amgen Kft. Tel.: +36 1 35 44 Danmark Amgen, filial af Amgen AB, Sverige Tlf: +45 39617Malta Amgen B.V. The Netherlands Tel: +31 (0)76 5732Deutschland AMGEN GmbH Tel.: +49 89 1490Nederland Amgen B.V. Tel: +31 (0)76 5732Eesti Amgen Switzerland AG Vilniaus filialas Tel: +372 586 09Norge Amgen AB Tel: +47 23308<br/>Amgen . . .<br/>.: +30 210 3447 sterreich Amgen GmbH<br/>Tel: +43 (0)1 50 Espa a Amgen S.A. Tel: +34 93 600 18 Polska Amgen Biotechnologia Sp. z o.o. Tel.: +48 22 581 3France Amgen S.A.S. T l: +33 (0)9 69 363 Portugal Amgen Biofarmac utica, Lda. Tel: +351 21 4220Hrvatska Amgen d.o.o. Tel: +385 (0)1 562 57 Rom nia Amgen Rom nia SRL Tel: +4021 527 3Ireland Amgen Ireland Limited Tel: +353 1 8527Slovenija AMGEN zdravila d.o.o. Tel: +386 (0)1 585 1 sland Vistor hf. S mi: +354 535 7Slovensk republika Amgen Slovakia s.r.o. Tel: +421 2 321 114 Italia Amgen S.r.l. Tel: +39 02 6241Suomi/Finland Amgen AB, sivuliike Suomessa/Amgen AB, filial i Finland Puh/Tel: +358 (0)9 54900K<br/>C.A. Papaellinas Ltd .: +357 22741 Sverige Amgen AB<br/>Tel: +46 (0)8 6951Latvija Amgen Switzerland AG R gas fili le Tel: +371 257 25United Kingdom (Northern Ireland) Amgen Limited Tel: +44 (0)1223 420This leaflet was last revised in</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp168192a0c6d5270d5bcdb3cfa6cdd926"/>
<resource>
<MedicinalProductDefinition>
<id value="mp168192a0c6d5270d5bcdb3cfa6cdd926"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp168192a0c6d5270d5bcdb3cfa6cdd926"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp168192a0c6d5270d5bcdb3cfa6cdd926</b></p><a name="mp168192a0c6d5270d5bcdb3cfa6cdd926"> </a><a name="hcmp168192a0c6d5270d5bcdb3cfa6cdd926"> </a><a name="mp168192a0c6d5270d5bcdb3cfa6cdd926-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/04/292/001 – 30 mg carton with 14 tablets</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Mimpara 30 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/04/292/001 – 30 mg carton with 14 tablets"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Mimpara 30 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
